Research Study for Major Depressive Disorder: Investigation of Glutamate Medications

This randomised, double-blind, placebo-controlled trial (n=26) aims to investigate the safety and efficacy of ketamine and riluzole in patients with treatment-resistant major depressive disorder. Additionally, the study will assess whether lamotrigine can mitigate ketamine-associated side effects.

Conducted by Baylor College of Medicine, the trial enrolled ketamine-responsive patients and randomly assigned them to either riluzole or placebo for a four-week continuation phase. The primary outcome was measured using the Montgomery-Åsberg Depression Rating Scale (MADRS) to evaluate depressive symptoms following ketamine infusion. Secondary outcomes included the effectiveness of lamotrigine in reducing ketamine’s psychotomimetic effects.

Topic Depression Treatment-Resistant Depression
Compound Placebo Ketamine
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Baylor College of Medicine
This company doesn't have a full profile yet, it is linked to a clinical trial.

National Alliance for Research on Schizophrenia and Depression
This company doesn't have a full profile yet, it is linked to a clinical trial.

National Center for Research Resources
This company doesn't have a full profile yet, it is linked to a clinical trial.

Measures Used

Montgomery-Asberg Depression Rating Scale
A ten-item diagnostic questionnaire used to measure the severity of depressive symptoms in patients with mood disorders.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.